MedTrace Logo

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

NCT00875277 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its combination with calcipotriol and betamethasone using a psoriasis plaque test method.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

LEO 29102 cream

DRUG

LEO 29102 Cream Vehicle

DRUG

Betamethasone Dipropionate Cream

DRUG

LEO 29102 Plus Calcipotriol Cream

DRUG

LEO 29102 Plus Betamethasone Dipropionate

DRUG

Daivobet® Ointment

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Director, International Clinical Development, MD · LEO Pharma

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-05-31
Completion
2009-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875277 on ClinicalTrials.gov